Clinical trials: Age Related Maculopathy
Retinal Hemorrhage, Macular Degeneration
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor.
- Trial name
- NCT00538538
- Testing
- vitrectomy with subretinal lucentis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Corewell Health East
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Post Intravitreal Injection Topical NSAID vs. Patching
A prospective randomized trial, to evaluate post-injection comfort measures comparing topical NSAID (nepafenac 0.3% suspension) and patching.
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT03918590
- Testing
- nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The New York Eye & Ear Infirmary
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Age-Related Macular Degeneration, Lens, Intraocular
Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss.
- Conditions
- Age-Related Macular Degeneration, Lens, Intraocular, Myopic Maculopathy
- Trial name
- NCT03882606
- Testing
- Scharioth Macula Lens (SML, Medicontur)
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Consorci Sanitari de Terrassa
Macular Degeneration, Age Related
Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients
The best treatment to prevent the evolution of early and intermediate forms of dAMD to atrophic degeneration is PhotoBioModulation (PBM).
- Trial name
- PBM-dAMD (NCT06582511)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Francesco Bandello
Macular Degeneration
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular…
- Trial name
- NCT00745511
- Testing
- ORA102 and Avastin, Avastin
- Where
- 5 sites in Israel
- Volunteers
- 96 people
- Sponsor
- Ora Bio Ltd.
Age-related Macular Degeneration
Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV)
A device has been developed that has eye trackers integrated within the Head Mounted Display (HMD) and can remap text and images around the scotoma in real time to prevent information loss from a central scotoma.
- Trial name
- HETALCEV (NCT02829606)
- Testing
- small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Geographic Atrophy
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related…
- Trial name
- NCT06161584
- Testing
- Pegcetacoplan
- Where
- 34 sites in United States
- Volunteers
- 300 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age - Related Macular Degeneration (AMD)
Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration
This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN…
- Trial name
- NCT07121127
- Testing
- FSN+Vitamin supplement, Vitamin Supplements
- Volunteers
- 38 people
- Sponsor
- Zhiming Yan
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Age-Related Maculopathy
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular…
- Trial name
- NCT00056823
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 168 people
- Sponsor
- Genentech, Inc.
Age Related Macular Degeneration
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Age Related Macular Degeneration (AMD) is the leading cause of blindness in North America. This condition causes a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp…
- Trial name
- NCT01363570
- Testing
- Ranibizumab
- Where
- 2 sites in Canada
- Volunteers
- 70 people
- Sponsor
- McMaster University
Macular Degeneration
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin…
- Trial name
- AQUILA (NCT03470103)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 4 sites in Argentina, Colombia and 2 more
- Volunteers
- 643 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
The purpose of this study is to obtain conjunctiva and tenon's capsule thickness measurements in vivo using spectral domain-optical coherence tomography (SD-OCT) in participants with nAMD/DME and age-matched healthy subjects.
- Trial name
- NCT06723288
- Where
- 20 sites in Spain
- Volunteers
- 736 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Macular Degeneration, Age-Related, Diabetic Retinopathy
Visual Enhancement Device in Low Vision Patients
This study will be a prospective, non-randomized study of low-vision individuals diagnosed with either age-related macular degeneration (AMD) or diabetic macular edema with ETDRS visual acuity from 20/60 to 20/400 in both eyes…
- Trial name
- Evergaze (NCT03794752)
- Testing
- Head-Mounted Visual Enhancement Device
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Age-related Macular Degeneration
Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration
- Trial name
- PROTECT (NCT02302989)
- Testing
- Ranibizumab 0.5mg
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leonard Feiner, MD, PhD
Dry Age-related Macular Degeneration
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry…
- Trial name
- NCT06165068
- Testing
- Aspirin 81Mg Ec Tab, Clopidogrel, N-acetylcysteine
- Where
- Thailand
- Volunteers
- 174 people
- Sponsor
- Navamindradhiraj University
Neovascular Age-related Macular Degeneration (nAMD)
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
- Trial name
- NCT05904691
- Testing
- OCU-10-C-110 for Injection
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Ocugenix Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.